Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1846, Issue 2, 2014, Pages 353-365

  Vu, Thuy ^a,b   Sliwkowski, Mark X ^c   Claret, Francois X ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c GENENTECH INC   (United States)

Author keywords

Combination approaches; HER2 positive breast cancer; Targeted therapy; Trastuzumab resistance

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUPARLISIB; CAPECITABINE; CARBOPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DACTOLISIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MM 111; NAVELBINE; NERATINIB; PACLITAXEL; PANOBINOSTAT; PERTEJA; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROTEIN KINASE B INHIBITOR; RETASPIMYCIN; RIDAFOROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; DRUG CONJUGATION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HER2 GENE; HUMAN; INFLAMMATION; INFLAMMATORY BREAST CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STOMACH CANCER; BREAST NEOPLASMS; CHEMISTRY; DRUG RESISTANCE; FEMALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PRECISION MEDICINE; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84906707906     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.07.007     Document Type: Review

References (124)

1. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
2. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Eroles P., Bosch A., Perez-Fidalgo J.A., Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 2012, 38:698-707.
4. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62:4132-4141.
5. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 2012, 9:16-32.
6. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., von Minckwitz F., Visco V., Bee M., Buyse B., Bendahmane I., Tabah-Fisch M.A., Lindsay A., Riva J., Crown G. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 2011, 365:1273-1283. Breast Cancer International Research.
7. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
8. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2009, 27:5838-5847.
9. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001, 61:4744-4749.
10. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20:719-726.
11. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
12. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H., Sledge G., Koehler M., Ellis C., Casey M., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 2010, 28:1124-1130.
13. Blackwell K.L., Burstein H.J., Storniolo A.M., Rugo H.S., Sledge G., Aktan G., Ellis C., Florance A., Vukelja S., Bischoff J., Baselga J., O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J. Clin. Oncol. 2012, 30:2585-2592.
14. von Minckwitz G., du Bois A., Schmidt M., Maass N., Cufer T., de Jongh F.E., Maartense E., Zielinski C., Kaufmann M., Bauer W., Baumann K.H., Clemens M.R., Duerr R., Uleer C., Andersson M., Stein R.C., Nekljudova V., Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J. Clin. Oncol. 2009, 27:1999-2006.
15. von Minckwitz G., Schwedler K., Schmidt M., Barinoff J., Mundhenke C., Cufer T., Maartense E., de Jongh F.E., Baumann K.H., Bischoff J., Harbeck N., Luck H.J., Maass N., Zielinski C., Andersson M., Stein R.C., Nekljudova V., Loibl S. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur. J. Cancer 2011, 47:2273-2281. G.B.s. group, i. participating.
16. Al-Lazikani B., Banerji U., Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012, 30:679-692.
17. Rodon J., Perez J., Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist 2010, 15:37-50.
18. Yap T.A., Omlin A., de Bono J.S. Development of therapeutic combinations targeting major cancer signaling pathways. J. Clin. Oncol. 2013, 31:1592-1605.
19. Ritter C.A., Perez-Torres M., Rinehart C., Guix M., Dugger T., Engelman J.A., Arteaga C.L. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 2007, 13:4909-4919.
20. Christianson T.A., Doherty J.K., Lin Y.J., Ramsey E.E., Holmes R., Keenan E.J., Clinton G.M. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998, 58:5123-5129.
21. Saez R., Molina M.A., Ramsey E.E., Rojo F., Keenan E.J., Albanell J., Lluch A., Garcia-Conde J., Baselga J., Clinton G.M. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. 2006, 12:424-431.
22. Scaltriti M., Rojo F., Ocana A., Anido J., Guzman M., Cortes J., Di Cosimo S., Matias-Guiu X., Ramon y Cajal S., Arribas J., Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 2007, 99:628-638.
23. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., Scher H.I., Sliwkowski M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127-137.
24. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
25. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
26. Nahta R., Hung M.C., Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64:2343-2346.
27. Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69:9330-9336.
28. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., Bianchi G., Cortes J., McNally V.A., Ross G.A., Fumoleau P., Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010, 28:1138-1144.
29. Sliwkowski M.X., Mellman I. Antibody therapeutics in cancer. Science 2013, 341:1192-1198.
30. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M., Group C.S. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012, 366:109-119.
31. Swain S.M., Kim S.B., Cortes J., Ro J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes M.C., Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013, 14:461-471.
32. Gradishar W.J. HER2 therapy-an abundance of riches. N. Engl. J. Med. 2012, 366:176-178.
33. Swain S.M., Ewer M.S., Cortes J., Amadori D., Miles D., Knott A., Clark E., Benyunes M.C., Ross G., Baselga J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 2013, 18:257-264.
34. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
35. Nielsen D.L., Andersson M., Kamby C. HER2-targeted therapy in breast cancer monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat. Rev. 2009, 35:121-136.
36. Lin N.U., Winer E.P. Brain metastases: the HER2 paradigm. Clin. Cancer Res. 2007, 13:1648-1655.
37. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., Gilmer T.M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1:85-94.
38. Xia W., Mullin R.J., Keith B.R., Liu L.H., Ma H., Rusnak D.W., Owens G., Alligood K.J., Spector N.L. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002, 21:6255-6263.
39. Xia W., Husain I., Liu L., Bacus S., Saini S., Spohn J., Pry K., Westlund R., Stein S.H., Spector N.L. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007, 67:1170-1175.
40. Scaltriti M., Chandarlapaty S., Prudkin L., Aura C., Jimenez J., Angelini P.D., Sanchez G., Guzman M., Parra J.L., Ellis C., Gagnon R., Koehler M., Gomez H., Geyer C., Cameron D., Arribas J., Rosen N., Baselga J. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin. Cancer Res. 2010, 16:2688-2695.
41. Hutchinson L. Targeted therapies: lapatinib is effective in patients with p95HER2-positive tumors. Nat. Rev. Clin. Oncol. 2010, 7:358.
42. Rusnak D., Gilmer T.M. The discovery of lapatinib (GW572016). Mol. Cancer Ther. 2011, 10:2019.
43. Baselga J., Bradbury I., Eidtmann H., Di Cosimo S., de Azambuja E., Aura C., Gomez H., Dinh P., Fauria K., Van Dooren V., Aktan G., Goldhirsch A., Chang T.W., Horvath Z., Coccia-Portugal M., Domont J., Tseng L.M., Kunz G., Sohn J.H., Semiglazov V., Lerzo G., Palacova M., Probachai V., Pusztai L., Untch M., Gelber R.D., Piccart-Gebhart M., Neo A.S.T. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
44. Perez E.A., Koehler M., Byrne J., Preston A.J., Rappold E., Ewer M.S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 2008, 83:679-686.
45. Minkovsky N., Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr. Opin. Investig. Drugs 2008, 9:1336-1346.
46. Lin N.U., Winer E.P., Wheatley D., Carey L.A., Houston S., Mendelson D., Munster P., Frakes L., Kelly S., Garcia A.A., Cleator S., Uttenreuther-Fischer M., Jones H., Wind S., Vinisko R., Hickish T. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat. 2012, 133:1057-1065.
47. Burstein H.J., Sun Y., Dirix L.Y., Jiang Z., Paridaens R., Tan A.R., Awada A., Ranade A., Jiao S., Schwartz G., Abbas R., Powell C., Turnbull K., Vermette J., Zacharchuk C., Badwe R. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 2010, 28:1301-1307.
48. Lopez-Tarruella S., Jerez Y., Marquez-Rodas I., Martin M. Neratinib (HKI-272) in the treatment of breast cancer. Future Oncol. 2012, 8:671-681.
49. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 2010, 10:345-352.
50. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., Fuh G. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
51. McDonagh C.F., Huhalov A., Harms B.D., Adams S., Paragas V., Oyama S., Zhang B., Luus L., Overland R., Nguyen S., Gu J., Kohli N., Wallace M., Feldhaus M.J., Kudla A.J., Schoeberl B., Nielsen U.B. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 2012, 11:582-593.
52. Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 2005, 23:1137-1146.
53. LoRusso P.M., Weiss D., Guardino E., Girish S., Sliwkowski M.X. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 2011, 17:6437-6447.
54. Junttila T.T., Li G., Parsons K., Phillips G.L., Sliwkowski M.X. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 2011, 128:347-356.
55. Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blattler W.A., Lambert J.M., Chari R.V., Lutz R.J., Wong W.L., Jacobson F.S., Koeppen H., Schwall R.H., Kenkare-Mitra S.R., Spencer S.D., Sliwkowski M.X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68:9280-9290.
56. Hurvitz S.A., Dirix L., Kocsis J., Bianchi G.V., Lu J., Vinholes J., Guardino E., Song C., Tong B., Ng V., Chu Y.W., Perez E.A. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 2013, 31:1157-1163.
57. Boyraz B., Sendur M.A., Aksoy S., Babacan T., Roach E.C., Kizilarslanoglu M.C., Petekkaya I., Altundag K. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr. Med. Res. Opin. 2013, 29:405-414.
58. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
59. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
60. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., van de Vijver M.J., Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
61. She Q.B., Chandarlapaty S., Ye Q., Lobo J., Haskell K.M., Leander K.R., DeFeo-Jones D., Huber H.E., Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008, 3:e3065.
62. DeGraffenried L.A., Fulcher L., Friedrichs W.E., Grunwald V., Ray R.B., Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 2004, 15:1510-1516.
63. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
64. Raynaud F.I., Eccles S.A., Patel S., Alix S., Box G., Chuckowree I., Folkes A., Gowan S., De Haven Brandon A., Di Stefano F., Hayes A., Henley A.T., Lensun L., Pergl-Wilson G., Robson A., Saghir N., Zhyvoloup A., McDonald E., Sheldrake P., Shuttleworth S., Valenti M., Wan N.C., Clarke P.A., Workman P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 2009, 8:1725-1738.
65. Raynaud F.I., Workman P. Discovering and developing PI3 kinase inhibitors for cancer: rapid progress through academic-biotech-pharma interactions. Mol. Cancer Ther. 2011, 10:2017-2018.
66. Hynes N.E., Dey J.H. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 2009, 15:353-355.
67. Yao E., Zhou W., Lee-Hoeflich S.T., Truong T., Haverty P.M., Eastham-Anderson J., Lewin-Koh N., Gunter B., Belvin M., Murray L.J., Friedman L.S., Sliwkowski M.X., Hoeflich K.P. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res. 2009, 15:4147-4156.
68. Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., Schnell C., Guthy D., Nagel T., Wiesmann M., Brachmann S., Fritsch C., Dorsch M., Chene P., Shoemaker K., De Pover A., Menezes D., Martiny-Baron G., Fabbro D., Wilson C.J., Schlegel R., Hofmann F., Garcia-Echeverria C., Sellers W.R., Voliva C.F. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 2012, 11:317-328.
69. Dancey J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 2010, 7:209-219.
70. Miller T.W., Forbes J.T., Shah C., Wyatt S.K., Manning H.C., Olivares M.G., Sanchez V., Dugger T.C., de Matos Granja N., Narasanna A., Cook R.S., Kennedy J.P., Lindsley C.W., Arteaga C.L. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin. Cancer Res. 2009, 15:7266-7276.
71. Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 1975, 28:721-726.
72. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
73. O'Donnell A., Faivre S., Burris H.A., Rea D., Papadimitrakopoulou V., Shand N., Lane H.A., Hazell K., Zoellner U., Kovarik J.M., Brock C., Jones S., Raymond E., Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 2008, 26:1588-1595.
74. Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., Xiong Y., Zhang S., Krop I.E., Winer E.P., Kindelberger D.W., Coviello J., Sahin A.A., Nunez R., Hortobagyi G.N., Yu D., Esteva F.J. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 2011, 29:3126-3132.
75. Stern H.M. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci. Transl. Med. 2012, 4:127rv122.
76. Nahta R., O'Regan R.M. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin. Breast Cancer 2010, 10(Suppl. 3):S72-S78.
77. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
78. Eichhorn P.J., Gili M., Scaltriti M., Serra V., Guzman M., Nijkamp W., Beijersbergen R.L., Valero V., Seoane J., Bernards R., Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008, 68:9221-9230.
79. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
80. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
81. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
82. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., Ueno Y., Hatch H., Majumder P.K., Pan B.S., Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 2010, 9:1956-1967.
83. Sangai T., Akcakanat A., Chen H., Tarco E., Wu Y., Do K.A., Miller T.W., Arteaga C.L., Mills G.B., Gonzalez-Angulo A.M., Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin. Cancer Res. 2012, 18:5816-5828.
84. Yap T.A., Yan L., Patnaik A., Fearen I., Olmos D., Papadopoulos K., Baird R.D., Delgado L., Taylor A., Lupinacci L., Riisnaes R., Pope L.L., Heaton S.P., Thomas G., Garrett M.D., Sullivan D.M., de Bono J.S., Tolcher A.W. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29:4688-4695.
85. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
86. Grant S., Dai Y. Histone deacetylase inhibitors and rational combination therapies. Adv. Cancer Res. 2012, 116:199-237.
87. Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., Yamaguchi H., Wang H.G., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2003, 2:971-984.
88. Wagner J.M., Hackanson B., Lubbert M., Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 2010, 1:117-136.
89. Campone P.C.M., Amadori D., Pronzato P., Wardley A., McBride K., Fandi A. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety, efficacy and pharmacokinetic results. Cancer Res. 2009, 69:6101.
90. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 2010, 10:537-549.
91. Leow C.C., Chesebrough J., Coffman K.T., Fazenbaker C.A., Gooya J., Weng D., Coats S., Jackson D., Jallal B., Chang Y. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol. Cancer Ther. 2009, 8:2131-2141.
92. Scaltriti M., Serra V., Normant E., Guzman M., Rodriguez O., Lim A.R., Slocum K.L., West K.A., Rodriguez V., Prudkin L., Jimenez J., Aura C., Baselga J. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Mol. Cancer Ther. 2011, 10:817-824.
93. Chandarlapaty S., Scaltriti M., Angelini P., Ye Q., Guzman M., Hudis C.A., Norton L., Solit D.B., Arribas J., Baselga J., Rosen N. Inhibitors of HSP90 block p95-HER2 signaling in trastuzumab-resistant tumors and suppress their growth. Oncogene 2010, 29:325-334.
94. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8324-8328.
95. Grenert J.P., Sullivan W.P., Fadden P., Haystead T.A., Clark J., Mimnaugh E., Krutzsch H., Ochel H.J., Schulte T.W., Sausville E., Neckers L.M., Toft D.O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 1997, 272:23843-23850.
96. Schulte T.W., Neckers L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42:273-279.
97. Arteaga C.L. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?. Clin. Cancer Res. 2011, 17:4919-4921.
98. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., Cropp G.F., Johnson R.G., Hannah A.L., Hudis C.A. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 2007, 25:5410-5417.
99. Modi S., Stopeck A., Linden H., Solit D., Chandarlapaty S., Rosen N., D'Andrea G., Dickler M., Moynahan M.E., Sugarman S., Ma W., Patil S., Norton L., Hannah A.L., Hudis C. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 2011, 17:5132-5139.
100. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 2004, 4:505-518.
101. King E.R., Wong K.K. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent. Pat. Anticancer Drug Discov. 2012, 7:14-30.
102. Gooch J.L., Van Den Berg C.L., Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res. Treat. 1999, 56:1-10.
103. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 2012, 12:159-169.
104. Buck E., Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin. Investig. Drugs 2011, 20:605-621.
105. Harris L.N., You F., Schnitt S.J., Witkiewicz A., Lu X., Sgroi D., Ryan P.D., Come S.E., Burstein H.J., Lesnikoski B.A., Kamma M., Friedman P.N., Gelman R., Iglehart J.D., Winer E.P. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 2007, 13:1198-1207.
106. Lu Y., Zi X., Zhao Y., Mascarenhas D., Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001, 93:1852-1857.
107. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65:11118-11128.
108. Lu Y., Zi X., Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 2004, 108:334-341.
109. Esparis-Ogando A., Ocana A., Rodriguez-Barrueco R., Ferreira L., Borges J., Pandiella A. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann. Oncol. 2008, 19:1860-1869.
110. Rodon J., DeSantos V., Ferry R.J., Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol. Cancer Ther. 2008, 7:2575-2588.
111. Carboni J.M., Wittman M., Yang Z., Lee F., Greer A., Hurlburt W., Hillerman S., Cao C., Cantor G.H., Dell-John J., Chen C., Discenza L., Menard K., Li A., Trainor G., Vyas D., Kramer R., Attar R.M., Gottardis M.M. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol. Cancer Ther. 2009, 8:3341-3349.
112. McKian K.P., Haluska P. Cixutumumab. Expert Opin. Investig. Drugs 2009, 18:1025-1033.
113. Rowinsky E.K., Youssoufian H., Tonra J.R., Solomon P., Burtrum D., Ludwig D.L. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 2007, 13:5549s-5555s.
114. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.
115. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997, 57:963-969.
116. Banerjee S., Dowsett M., Ashworth A., Martin L.A. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat. Clin. Pract. Oncol. 2007, 4:536-550.
117. Konecny G.E., Meng Y.G., Untch M., Wang H.J., Bauerfeind I., Epstein M., Stieber P., Vernes J.M., Gutierrez J., Hong K., Beryt M., Hepp H., Slamon D.J., Pegram M.D. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res. 2004, 10:1706-1716.
118. Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 2004, 9(Suppl. 1):43-49.
119. Gianni L., Romieu G.H., Lichinitser M., Serrano S.V., Mansutti M., Pivot X., Mariani P., Andre F., Chan A., Lipatov O., Chan S., Wardley A., Greil R., Moore N., Prot S., Pallaud C., Semiglazov V. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J. Clin. Oncol. 2013, 31:1719-1725.
120. Abramson V., Arteaga C.L. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin. Cancer Res. 2011, 17:952-958.
121. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145. American Society of Clinical Oncology, College of American PathologistsCollege of American Pathologists.
122. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., Brown A., Yothers G., Anderson S., Smith R., Wickerham D.L., Wolmark N. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J. Natl. Cancer Inst. 2002, 94:852-854.
123. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 2008, 358:1409-1411.
124. Rexer B.N., Engelman J.A., Arteaga C.L. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009, 8:18-22.